Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Tietjen, Ian ^a   Hovingh, G Kees ^b   Singaraja, Roshni R ^a,c   Radomski, Chris ^a   Barhdadi, Amina ^d   McEwen, Jason ^a   Chan, Elden ^a   Mattice, Maryanne ^a   Legendre, Annick ^a   Franchini, Patrick L ^a   Dubé, Marie Pierre ^d   Kastelein, John J P ^b   Hayden, Michael R ^c  

^a Xenon Pharmaceuticals Inc   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SERINE; TRYPTOPHAN;

ABCA1 GENE; ADULT; ARTICLE; CAUCASIAN; CETP GENE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILY; FEMALE; GALNT2 GENE; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; LCAT GENE; LIPG GENE; LPL GENE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NUCLEOTIDE SEQUENCE; PHENOTYPE; RNA SPLICING;

AGED; ALTERNATIVE SPLICING; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPASE; MALE; MIDDLE AGED; MUTATION; N-ACETYLGALACTOSAMINYLTRANSFERASES; PHENOTYPE; SEQUENCE ANALYSIS, DNA;

EID: 84865406477     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037437     Document Type: Article

References (48)

1. Ali M, Beusenberg M, Bloessner M, Boschi Pinto C, Briand S, et al. (2009) World health statistics 2009. World Health Organization. Available: http://www.who.int/whosis/whostat/EN_WHS09_Full.pdf.
2. Plump AS, Lum PY, (2009) Genomics and cardiovascular drug development. J Am Coll Cardiol 53: 1089-1100.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR, (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714.
4. Muntner P. Lee F, Astor BC, (2010) Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: The Atherosclerosis Risk in Communities Study. Am J Med Sci 341: 173-180.
5. von Eckardstein A, Hersberger M, Rohrer L, (2005) Current understanding of the metabolism and biological actions of HDL. Curr Op Clin Nutr Metab Care 8: 147-152.
6. Barter PJ, Puranik R, Rye KA, (2007) New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9: 493-498.
7. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713.
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122.
9. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, et al. (2010) Safety of Anacetrapib in patients with or at high risk for coronary artery disease. N Engl J Med 363: 2406-2415.
10. Bauer RC, Stylianou IO, Rader DJ, (2011) Functional validation of new pathways in lipoprotein metabolism identified by human genetics. Curr Opin Lipidol 22: 123-128.
11. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, et al. (1990) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323: 1234-1238.
12. Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, et al. (1991) A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci 88: 4855-4859.
13. Reymer PW, Gagné E, Groenemeyer BE, Zhang H, Forsyth I, et al. (1995) A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 10: 28-34.
14. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, et al. (1999) Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22: 336-345.
15. Clee SM, Kastelein JJP, van Dam M, Marcil M, Roomp K, et al. (2000) Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 106: 1263-1270.
16. van der Steeg WA, Hovingh GK, Klerkx AH, Hutten BA, Nootenboom IC, et al. (2007) Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J Lipid Res 48: 674-682.
17. Edmondson AC, Brown RJ, Kathiresan S, Cupples LA, Demissie S, et al. (2009) Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 119: 1042-1050.
18. Klos KLE, Kullo IJ, (2007) Genetic determinants of HDL: Monogenic disorders and contributions to variation. Curr Opin Cardiol 23: 344-351.
19. Weissglas-Volkov D, Pajukanta P, (2010) Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 51: 2032-2057.
20. Ishida T, Choi S, Kundu RK, Hirata K, Rubin EM, et al. (2003) Endothelial lipase is a major determinant of HDL level. J Clin Invest 111: 347-355.
21. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ, (2003) Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 111: 357-362.
22. Khetarpal SA, Edmondson AC, Raghavan A, Heeli H, Jin W, et al. (2011) Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol. PLoS Genet 7: e1002393.
23. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ, (2002) Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 106: 1321-1326.
24. Gauthier A, Lau P, Zha X, Milne R, McPherson R, (2005) Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 25: 2177-2184.
25. Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, et al. (1985) Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 58: 175-186.
26. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, et al. (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342: 448-451.
27. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, et al. (1997) Substrate specificities of the three members of the human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1,-T2, and -T3. J Biol Chem 272: 23503-23514.
28. Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, et al. (2011) Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell Metab 14: 811-818.
29. von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, et al. (1991) Apolipoprotein C-III(Lys58→Glu): Identification of an Apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 87: 1724-1731.
30. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322: 1702-1705.
31. Heiss G, Johnson NJ, Reiland S, Davis CE, Tyroler HA, (1980) The epidemiology of plasma high-density lipoprotein cholesterol levels. The Lipid Research Clinics Program Prevalence Study. Circulation 62: IV116-136.
32. Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, et al. (1999) Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354: 1341-1346.
33. Rogler G, Trumbach B, Klima B, Lackner KJ, Schmitz G, (1995) HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol 15: 683-690.
34. Rogozin IB, Milanesi L, (1997) Analysis of donor splice signals in different organisms. J Mol Evol 45: 50-59.
35. Ramensky V, Bork P, Sunyaev S, (2002) Humans non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
36. Neale BM, Rivas MA, Voight BF, Altshuler D, Devlin B, et al. (2011) Testing for an unusual distribution of rare variants. PLoS Genet 7: e1001322.
37. Morgenthaler S, Thilly WG, (2007) A strategy to discovery genes that carry multi-allelic or mono-allelic risk for common diseases: A cohort allelic sums test (CAST). Mutation Res 615: 28-56.
38. Li B, Leal SM, (2008) Methods for detecting associations with rare variants for common diseases: Application to analysis of sequence data. Am J Hum Genet 83: 311-321.
39. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, et al. (1997) The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38: 191-205.
40. Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, et al. (2004) A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 44: 1429-1435.
41. Khovidhunkit W, Chartyingcharoen P, Siriwong S, Limumpornpetch P, Plengpanich W, (2012) Resequencing CETP, LIPC, and LIPG genes in Thai subjects with hyperalphalipoproteinemia. Am J Cardiol doi:10.1016/j.amjcard.2012.02.052.
42. Strauss JG, Frank S, Kratky D, Hammerle G, Hrzenjak A, et al. (2001) Adenovirus-mediated rescue of lipoprotein lipase-deficient mice. Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice. J Biol Chem 276: 36083-36090.
43. Merkel M, Eckel RH, Goldberg IJ, (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997-2006.
44. Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, et al. (2009) Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesterol ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 68: 535-545.
45. Ku CS, Naidoo N, Pawitan Y, (2011) Revisiting Mendelian disorders through exome sequencing. Hum Genet 129: 351-370.
46. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, et al. (2009) Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27: 182-189.
47. Tietjen I, Hovingh GK, Singaraja R, Radomski C, McEwen J, et al. (2012) Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta 1821: 416-424.
48. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872.